Antisense Bcl-2 oligonucleotide uptake in human transitional cell carcinoma

European Urology

Volumn 40, Issue 6, 2001, Pages 685-695

  Duggan, Brian J ^a   Cotter, Finbarr E ^d   Kelly, John D ^c   Hamilton, Peter W ^a   McCallion, Kevin ^a   Harkin, Denis ^a   Gardiner, Tom ^a   Anderson, Neil ^b   Keane, Patrick F ^c   Johnston, Samuel R ^c   Williamson, Kate E ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^b ROYAL VICTORIA HOSPITAL   (United Kingdom)

^c BELFAST CITY HOSPITAL   (United Kingdom)

^d ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

Author keywords

Antisense oligonucleotides; Bcl 2; Ex vivo model; Transitional cell carcinoma; Uptake

Indexed keywords

ANTISENSE OLIGODEOXYNUCLEOTIDE; PROTEIN BCL 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLADDER CARCINOMA; BLADDER TUMOR; CANCER CELL; CELL AGGREGATION; CELL LINE; CONTROLLED STUDY; DOWN REGULATION; DRUG BIOAVAILABILITY; FLOW CYTOMETRY; FLUORESCENCE; FLUORESCENCE MICROSCOPY; HUMAN; INCUBATION TIME; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN TRANSPORT; STAINING; TARGET CELL; TRANSITIONAL CELL CARCINOMA; UROTHELIUM;

ANIMALS; APOPTOSIS; CARCINOMA, TRANSITIONAL CELL; FLOW CYTOMETRY; FLUORESCEIN-5-ISOTHIOCYANATE; HUMANS; MICROSCOPY, FLUORESCENCE; OLIGODEOXYRIBONUCLEOTIDES, ANTISENSE; PROTO-ONCOGENE PROTEINS C-BCL-2; RNA, MESSENGER; SWINE; TUMOR CELLS, CULTURED; URINARY BLADDER NEOPLASMS;

EID: 18244367165     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1159/000049858     Document Type: Article

References (30)

1. Involvement of the bcl-2 gene in human follicular lymphoma
2. Bcl-2 gene family and the regulation of programmed cell death
3. Overexpression of Bcl-2 in bladder cancer cells inhibits apoptosis induced by cisplatin and adenoviral-mediated p53 gene transfer
4. Abnormal bcl-2 and pRb expression are independent correlates of radiation response in muscle-invasive bladder cancer
5. Overexpression of Bcl-2 enhances metastatic potential of human bladder cancer cells
6. Bcl-2/Bax expression and p53 gene status in human bladder cancer: Relationship to early recurrence with intravesical chemotherapy after resection
7. Bcl-2/ bax mRNA expression ratio as prognostic factor in low-grade urinary bladder cancer
8. Antisense oligonucleotides suppress B-cell lymphoma growth in a SCID-hu mouse model
9. Bcl-2 anti-sense therapy in patients with non-Hodgkin lymphoma
10. Liposomal targeting of Bcl-2 antisense oligonucleotides with enhanced stability into human myeloma cell lines
11. Liposomal delivery of methyl-phosphonate antisense oligodeoxynucleotides in chronic myelogenous leukemia
12. Phosphorothioate oligodeoxy-ribonucleotides dissociate from cationic lipids before entering nucleus
13. Antisense therapy for lymphomas
14. Chracterisation of oligonucleotide transport into living cells
15. Cellular distribution of phosphoroyhiaote oligonucleotide following intravenous administration in mice
16. Comparison of cellular binding and uptake of antisense phosphodiester, phosphorothiaote, and mixed phosphorothiaote and methylphosphonate oligonucleotides
17. Induction of apoptosis in small-cell lung cancer cells by an antisense oligodeoxynucleotide targeting the Bcl-2 coding sequence
18. A human tissue culture cell line from a transitional cell tumour of the urinary bladder: Growth, chromosome pattern and ultrastructure
19. Induction of apoptosis by mitomycin in an ex vivo model of bladder cancer
20. Effect of different chemical modified oligonucleotides on immune stimulation
21. Flow cytometric and microscopic characterization of the uptake and distribution of phosphorothioate oligonucleotides in human keratinocytes
22. Characterisation of the nuclear binding sites of oligodeoxy-ribonucleotides and their analogs
23. Analysis of oligonucleotide binding, internalisation and intracellular trafficking utilising a novel radiolabelled crosslinker
24. The spread and uptake pattern of intracerebrally administered oligonucleotides in nerve and glial cell populations of the rat brain
25. Intracellu-lar localization of oligonucleotides: Influence of fixative protocols
26. The cancer chromatin connection
27. BCG treatment of existing Ta, T1 tumours or carcinoma in situ of the bladder
28. Intracellular distribution of microinjected antisense oligonucleotides
29. Three-dimensional analysis of epithelial cell profileration
30. Apparent failure of current intravesical chemotherapy prophylaxis to influence the long-term course of superficial transitional cell carcinoma of the bladder